MedTrace Logo

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT02909452 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-25

No results posted yet for this study

Summary

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

Conditions

  • Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Bronchial Neoplasms
  • Lung Neoplasms
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Digestive System Neoplasms
  • Endocrine Gland Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Diseases
  • Breast Diseases
  • Renal Neoplasm
  • Solid Tumors

Interventions

DRUG

Entinostat

HDAC (histone deacetylase) inhibitor

DRUG

Pembrolizumab

A selective humanized monoclonal antibody (mAb)

Sponsors & Collaborators

Principal Investigators

  • Michael Meyers, MD, PhD · Syndax Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2019-07-17
Completion
2021-02-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02909452 on ClinicalTrials.gov